It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The PML::RARA fusion protein is the hallmark driver of Acute Promyelocytic Leukemia (APL) and disrupts retinoic acid signaling, leading to wide-scale gene expression changes and uncontrolled proliferation of myeloid precursor cells. While known to be recruited to binding sites across the genome, its impact on gene regulation and expression is under-explored. Using integrated multi-omics datasets, we characterize the influence of PML::RARA binding on gene expression and regulation in an inducible PML::RARA cell line model and APL patient ex vivo samples. We find that genes whose regulatory elements recruit PML::RARA are not uniformly transcriptionally repressed, as commonly suggested, but also may be upregulated or remain unchanged. We develop a computational machine learning implementation called Regulatory Element Behavior Extraction Learning to deconvolute the complex, local transcription factor binding site environment at PML::RARA bound positions to reveal distinct signatures that modulate how PML::RARA directs the transcriptional response.
The PML-RARA gene fusion is the characteristic driver of Acute Promyelocytic Leukaemia (APL) and is known to bind to the genome. Here, the authors characterise the impact of PML-RARA on gene regulation in APL cell lines and patient samples using transcriptomics, epigenomics, and machine learning.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 King’s College London, Department of Medical and Molecular Genetics, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
2 King’s College London, School of Immunology & Microbial Sciences, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 Hamad Bin Khalifa University, ICT Division, College of Science and Engineering, Doha, Qatar (GRID:grid.452146.0) (ISNI:0000 0004 1789 3191)
4 Hamad Bin Khalifa University, Qatar Computing Research Institute, Doha, Qatar (GRID:grid.452146.0) (ISNI:0000 0004 1789 3191)
5 King’s College London, Department of Medical and Molecular Genetics, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); Guy’s and St. Thomas’ NHS Foundation Trust, Department of Haematology, London, UK (GRID:grid.420545.2) (ISNI:0000 0004 0489 3985)
6 Hamad Bin Khalifa University, Education City, College of Health and Life Sciences, Doha, Qatar (GRID:grid.452146.0) (ISNI:0000 0004 1789 3191); Queen Mary University London, William Harvey Research Institute, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)